NCT02292966View on ClinicalTrials.gov

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Hepatitis C, Chronic
Interventions
DRUG

DCV/ASV/BCV

Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.

Trial Locations (2)

2010

St Vincent's Hospital, Sydney

2145

Westmead Hospital, Westmead

Sponsors

Lead Sponsor

Kirby Institute

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Kirby Institute

OTHER_GOV